Innovative psoriasis therapy is expected to be approved for IL-17A/F dual inhibitors, supported by EU CHMP

Yesterday, UCB announced that the European Medicines Agency (EMA) Committee for Human Medicines (CHMP) had published positive reports on the company’s ongoing IL-17A/IL-17F inhibitor bimekizumab (expected as Bimzelx).

The positive opinions of CHMP are supported by three phase 3 clinical trials BE VIVID, BE READY and BE SURE

In terms of safety, the most common treatment-related adverse events were nasopharyngitis, oral candidiasis and upper respiratory tract infections

The fully humanized monoclonal antibody bimekizumab can strongly and specifically neutralize IL-17A and IL-17F

▲Schematic diagram of the working mechanism of Bimekizumab (picture source: reference [2])

"We are very happy with today's decision.

Psoriasis is a chronic, inflammatory skin disease whose symptoms include red patches covered with silver scales, dryness, chapped, bleeding, and thickened, sunken, or raised nails

Reference materials:

[1] UCB Receives Positive CHMP Opinion Recommending Approval of BIMZELX[®*] (bimekizumab) in the EU for the Treatment of Adults with Moderate to Severe Plaque Psoriasis.